DOCSLIB.ORG

Loss-Of-Function Mutation in Thiamine Transporter 1 in a Family with Autosomal Dominant Diabetes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Loss-Of-Function Mutation in Thiamine Transporter 1 in a Family with Autosomal Dominant Diabetes 1084 Diabetes Volume 68, May 2019 Loss-of-Function Mutation in Thiamine Transporter 1 in a Family With Autosomal Dominant Diabetes Prapaporn Jungtrakoon,1,2,3 Jun Shirakawa,1,4 Patinut Buranasupkajorn,1,2,5 Manoj K. Gupta,1,4 Dario F. De Jesus,1,4 Marcus G. Pezzolesi,6 Aussara Panya,1,2,3 Timothy Hastings,2 Chutima Chanprasert,3 Christine Mendonca,2 Rohit N. Kulkarni,1,4 and Alessandro Doria1,2 Diabetes 2019;68:1084–1093 | https://doi.org/10.2337/db17-0821 Solute Carrier Family 19 Member 2 (SLC19A2) encodes cardiovascular, and neuroendocrine abnormalities such as thiamine transporter 1 (THTR1), which facilitates thia- optic atrophy (2), arrhythmia, heart defects (3,4), thyroid mine transport across the cell membrane. SLC19A2 function alterations (5), and seizures (6). homozygous mutations have been described as a cause Thiamine, also known as vitamin B1, acts as coenzyme of thiamine-responsive megaloblastic anemia (TRMA), of the cytosolic enzyme transketolase (TKT), which is part an autosomal recessive syndrome characterized by of the pentose phosphate pathway (PPP) responsible for megaloblastic anemia, diabetes, and sensorineural deaf- the generation of NADPH and ribose-5-phosphate— SLC19A2 ness. Here we describe a loss-of-function a precursor of high-energy ribonucleotides (e.g., ATP) mutation (c.A1063C: p.Lys355Gln) in a family with early- and nucleotides. Thiamine is also the coenzyme for several onset diabetes and mild TRMA traits transmitted in an SLC19A2 mitochondrial enzymes, including pyruvate dehydroge- autosomal dominant fashion. We show that - a a fi b nase (PDH), -ketoglutarate dehydrogenase ( -KGDH), de cient -cells are characterized by impaired thiamine a uptake, which is not rescued by overexpression of branched-chain -ketoglutarate dehydrogenase (BCKD), the p.Lys355Gln mutant protein. We further demonstrate and 2-hydroxyphytanoyl-CoA lyase. The megaloblastic ane- that SLC19A2 deficit causes impaired insulin secretion in mia associated with SLC19A2 mutations appears to be due conjunction with mitochondrial dysfunction, loss of pro- to impaired TKT activity, which, by reducing the availabil- tection against oxidative stress, and cell cycle arrest. ity of nucleotides, causes red cell precursors to continue to These findings link SLC19A2 mutations to autosomal grow in size without dividing. The coexistence of senso- dominant diabetes and suggest a role of SLC19A2 in rineural deafness and the other neurological and cardio- b-cell function and survival. vascular abnormalities found in the TRMA syndrome are suggestive of an underlying mitochondrial dysfunction, GENETICS/GENOMES/PROTEOMICS/METABOLOMICS which might be due, in part, to impaired PDH (7) and SLC19A2 encodes thiamine transporter 1 (THTR1), a trans- a-KGDH (8) activities causing defective energy production, membrane protein that facilitates the transport of thia- to which tissues with a high demand for energy, such as the mine by shielding its positive charge from the repulsive auditory, visual, cardiovascular, and central nervous sys- force of the membrane. Homozygous SLC19A2 mutations tems, are particularly sensitive (9–11). have been described as the cause of thiamine-responsive The form of diabetes that is part of the TRMA syndrome megaloblastic anemia (TRMA) (Online Mendelian Inheri- is nonautoimmune and is characterized by an insulin se- tance in Man [OMIM] #249270), a syndrome characterized cretion deficit and a time of onset ranging from birth to by megaloblastic anemia, diabetes, sensorineural deafness adolescence. Insulin treatment is usually needed, although (1), and the variable combination of other neurological, the insulin requirement may be reduced in some cases by 1Department of Medicine, Harvard Medical School, Boston, MA Corresponding author: Alessandro Doria, [email protected] 2 Section on Genetics and Epidemiology, Joslin Diabetes Center, Boston, MA Received 12 July 2017 and accepted 23 February 2019 3Section on Islet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, MA This article contains Supplementary Data online at http://diabetes 4Division of Molecular Medicine, Research Department, Faculty of Medicine, Siriraj .diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0821/-/DC1. Hospital, Mahidol University, Bangkok, Thailand 5Division of Hospital and Ambulatory Medicine, Department of Medicine, Faculty of © 2019 by the American Diabetes Association. Readers may use this article as Medicine, Chulalongkorn University, Bangkok, Thailand long as the work is properly cited, the use is educational and not for profit, and the 6Division of Nephrology and Hypertension, University of Utah School of Medicine, work is not altered. More information is available at http://www.diabetesjournals Salt Lake City, UT .org/content/license. diabetes.diabetesjournals.org Jungtrakoon and Associates 1085 high-dose thiamine supplementation (12,13). The TRMA approved by the Joslin Diabetes Center’s Committee on syndrome has been reported in .50 families worldwide Human Studies (CHS#5-05). Upon receipt, islets were (14). While in most cases heterozygous SLC19A2 mutation cultured overnight in Miami Media #1A (Cellgro). Mouse carriers have not been described as having diabetes, adult- islets were isolated from wild-type C57BL/6 mice. Islets onset glucose intolerance with or without a hearing defect were handpicked and cultured overnight in RPMI media was reported among these subjects in three TRMA kindreds containing 5 mmol/L glucose and 10% FBS. For immu- (15). The question as to whether a single allele defect of nostaining studies, islets were embedded in agarose and SLC19A2 may cause diabetes has never been addressed. In used. For insulin secretion studies, islets were starved in this study, we report a loss-of-function mutation in the Final Wash/Culture Media (Cellgro) for 5 h before being SLC19A2 gene linked, albeit with incomplete penetrance, stimulated with 10 nmol/L insulin. to autosomal dominant diabetes with mild TRMA clinical signs and show suggestive evidence for SLC19A2 deficiency Immunohistochemistry and Immunoblotting causing impaired insulin secretion and diabetes by de- Human and mouse islets were analyzed by immunostain- termining mitochondrial dysfunction, loss of protection ing using anti-THTR1 (sc-27656; Santa Cruz Biotechnol- against oxidative stress, and cell cycle arrest in b-cells. ogy) and anti-insulin (ab7842; Abcam). Images were taken with an LSM7 confocal laser scanning microscope (Carl RESEARCH DESIGN AND METHODS Zeiss). For immunoblotting, MIN6-m9 cells, mouse islets, Whole-Exome Sequencing or human islets were solubilized in M-PER lysis buffer Fifty-two extended families with autosomal dominant di- (Thermo Scientific) with protease inhibitors and phospha- abetes underwent whole-exome sequencing as reported by tase inhibitors (Sigma-Aldrich), and protein concentration Prudente et al. (16). Variants were filtered as previously was measured using a BCA protein assay kit (Pierce). described. Briefly, variants that were heterozygous, were Extracts were subjected to Western blotting with primary reported in public databases (dbSNP142, 1000 Genomes, antibodies overnight at 4°C. Mouse and human anti- and Exome Variant Server [EVS]) with frequency ,0.01, THTR1, anti–b-actin, and anti–a-tubulin antibodies were were shared by affected family members, and were poten- from Sigma-Aldrich (HPA016599), Cell Signaling Technol- tially deleterious as determined by a panel of prediction ogy (4970), and Abcam (ab7291), respectively. softwares were included in the analysis (16). In the former study, the focus was on variants that were located in genes Cellular Localization of SLC19A2-GFP Fusion Proteins with functional relevance to glucose metabolism as de- The coding sequence of the human SLC19A2 gene termined by an analysis with GeneDistiller (16). In the (NM_006996; OHu18269C [GenScript]) was subcloned current study, we reanalyzed those same exome sequenc- into the pAcGFP1-N1 vector (Addgene) at XhoI and AgeI ing data focusing on variants placed in a second set of sites. The SLC19A2-WT-GFP (GFP-tagged wild type [WT]) candidate genes, namely, genes that are mutated in rare construct was used as a template for generation of forms of syndromic diabetes. These included the WFS1, SLC19A2-K355Q-GFP (GFP-tagged mutant) by means of CISD2, ALMS1, and SLC19A2 genes, which are mutated in site-directed mutagenesis using the Q5 Site-Directed Mu- Wolfram type 1, Wolfram type 2, Alström, and TRMA tagenesis Kit (NEB). Primers for cloning and mutagenesis syndromes, respectively. Filtered variants were validated are provided in Supplementary Table 1. Plasmid con- and analyzed for segregation with diabetes in the families structs were transiently transfected into MIN6-m9 using by means of Sanger DNA sequencing. Variants were con- METAFECTENE PRO (Biontex). Twenty-four hours after sidered to segregate with diabetes if $80% of carriers .40 transfection, cells were trypsinized and transferred to years old had developed diabetes and there were no poly-L-lysine–coated glass-bottom dishes. Live cell imaging phenocopies whose phenotype was not consistent with was performed at 72 h after transfection with an LSM7 either type 1 or older-onset type 2 diabetes. confocal laser scanning microscope (Carl Zeiss). Cell Culture SLC19A2 Suppression and Quantitative RT-PCR The mouse insulinoma cell line MIN6-m9 (17) was kindly Analysis provided by Prof. S. Seino, Kobe University. Unless in- Lentiviral transduction particles (Sigma-Aldrich) carrying dicated otherwise,
Load more

Recommended publications
  • Family Phenotypic Heterogeneity Caused by Mitochondrial DNA Mutation A3243G Heterogeneidade Fenotípica De Uma Família Causada
    Alves D, et al. Phenotypic heterogeneity of inherited diabetes and deafness, Acta Med Port 2017 Jul-Aug;30(7-8):581-585 REFERENCES 1. Bywaters EG. Still’s disease in the adult. Ann Rheum Dis. 1971;30:121– with emphasis on organ failure. Semin Arthritis Rheum. 1987;17:39–57. 33. 9. Ohta A, Yamaguchi M, Tsunematsu T, Kasukawa R, Mizushima H, 2. Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult Kashiwagi H, et al. Adult Still’s disease: a multicenter survey of Japanese onset Still’s disease. Ann Rheum Dis. 2006;65:564–72. patients. J Rheumatol. 1990;17:1058–63. 3. Cheema GS, Quismorio FP. Pulmonary involvement in adult-onset Still’s 10. Cagatay Y, Gul A, Cagatay A, Kamali S, Karadeniz A, Inanc M, et al. disease. Curr Opin Pulm Med. 1999;5:305–9. Adult-onset Still’s disease. Int J Clin Pract. 2009;63:1050–5. 4. Zeng T, Zou YQ, Wu MF, Yang CD. Clinical features and prognosis 11. Riera E, Olivé A, Narváez J, Holgado S, Santo P, Mateo L, et al. CASO CLÍNICO of adult-onset still’s disease: 61 cases from China. J Rheumatol. Adult onset Still’s disease: review of 41 cases. Clin Exp Rheumatol. 2009;36:1026–31. 2011;29:331–6. 5. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, 12. Chen PD, Yu SL, Chen S, Weng XH. Retrospective study of 61 patients Kashiwagi H, et al. Preliminary criteria for classification of adult Still’s with adult-onset Still’s disease admitted with fever of unknown origin in disease.
    [Show full text]
  • Identification of P.A684V Missense Mutation in the WFS1 Gene As a Frequent Cause of Autosomal Dominant Optic Atrophy and Hearing
    RESEARCH ARTICLE Identification of p.A684V Missense Mutation in the WFS1 Gene as a Frequent Cause of Autosomal Dominant Optic Atrophy and Hearing Impairment Nanna D. Rendtorff,1 Marianne Lodahl,1 Houda Boulahbel,2 Ida R. Johansen,1 Arti Pandya,3 Katherine O. Welch,4 Virginia W. Norris,4 Kathleen S. Arnos,4 Maria Bitner-Glindzicz,5 Sarah B. Emery,6 Marilyn B. Mets,7 Toril Fagerheim,8 Kristina Eriksson,9 Lars Hansen,1 Helene Bruhn,10 Claes M€oller,11 Sture Lindholm,12 Stefan Ensgaard,13 Marci M. Lesperance,6 and Lisbeth Tranebjaerg1,14*,† 1Wilhelm Johannsen Centre for Functional Genome Research, Department of Cellular and Molecular Medicine (ICMM), The Panum Institute, University of Copenhagen, Copenhagen, Denmark 2Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark 3Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, Virginia 4Department of Biology, Gallaudet University, Washington DC 5UCL Institute of Child Health, London, UK 6Division of Pediatric Otolaryngology, Department of Otolaryngology-Head and Neck Surgery, UniversityofMichiganHealthSystem,AnnArbor,Michigan 7Departments of Ophthalmology and Surgery, Feinberg School of Medicine, Northwestern University, Evanston, Illinois 8Division of Child and Adolescent Health, Department of Medical Genetics, University Hospital of North Norway, Tromsø, Norway 9Department of Ophthalmology, Lundby Hospital, Gothenburg, Sweden 10Division of Metabolic Diseases, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden 11Department of Audiology/Disability Research (SIDR), O¨rebro University, Sweden 12Department of Audiology, County Hospital, Kalmar, Sweden 13Department of Psychiatrics, Stockholm, Sweden 14Department of Audiology, Bispebjerg Hospital, Copenhagen, Denmark Received 19 July 2010; Accepted 2 February 2011 Optic atrophy (OA) and sensorineural hearing loss (SNHL) are these additional eight families.
    [Show full text]
  • Antibodies Products
    Chapter 2 : Gentaur Products List • Human Signal peptidase complex catalytic subunit • Human Sjoegren syndrome nuclear autoantigen 1 SSNA1 • Human Small proline rich protein 2A SPRR2A ELISA kit SEC11A SEC11A ELISA kit SpeciesHuman ELISA kit SpeciesHuman SpeciesHuman • Human Signal peptidase complex catalytic subunit • Human Sjoegren syndrome scleroderma autoantigen 1 • Human Small proline rich protein 2B SPRR2B ELISA kit SEC11C SEC11C ELISA kit SpeciesHuman SSSCA1 ELISA kit SpeciesHuman SpeciesHuman • Human Signal peptidase complex subunit 1 SPCS1 ELISA • Human Ski oncogene SKI ELISA kit SpeciesHuman • Human Small proline rich protein 2D SPRR2D ELISA kit kit SpeciesHuman • Human Ski like protein SKIL ELISA kit SpeciesHuman SpeciesHuman • Human Signal peptidase complex subunit 2 SPCS2 ELISA • Human Skin specific protein 32 C1orf68 ELISA kit • Human Small proline rich protein 2E SPRR2E ELISA kit kit SpeciesHuman SpeciesHuman SpeciesHuman • Human Signal peptidase complex subunit 3 SPCS3 ELISA • Human SLAIN motif containing protein 1 SLAIN1 ELISA kit • Human Small proline rich protein 2F SPRR2F ELISA kit kit SpeciesHuman SpeciesHuman SpeciesHuman • Human Signal peptide CUB and EGF like domain • Human SLAIN motif containing protein 2 SLAIN2 ELISA kit • Human Small proline rich protein 2G SPRR2G ELISA kit containing protein 2 SCUBE2 ELISA kit SpeciesHuman SpeciesHuman SpeciesHuman • Human Signal peptide CUB and EGF like domain • Human SLAM family member 5 CD84 ELISA kit • Human Small proline rich protein 3 SPRR3 ELISA kit containing protein
    [Show full text]
  • Transporters
    Alexander, S. P. H., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP Collaborators (2019). The Concise Guide to Pharmacology 2019/20: Transporters. British Journal of Pharmacology, 176(S1), S397-S493. https://doi.org/10.1111/bph.14753 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1111/bph.14753 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Wiley at https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.14753. Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology (2019) 176, S397–S493 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters Stephen PH Alexander1 , Eamonn Kelly2, Alistair Mathie3 ,JohnAPeters4 , Emma L Veale3 , Jane F Armstrong5 , Elena Faccenda5 ,SimonDHarding5 ,AdamJPawson5 , Joanna L Sharman5 , Christopher Southan5 , Jamie A Davies5 and CGTP Collaborators 1School of Life Sciences,
    [Show full text]
  • Comprehensive Review on Lactate Metabolism in Human Health☆,☆☆
    Mitochondrion 17 (2014) 76–100 Contents lists available at ScienceDirect Mitochondrion journal homepage: www.elsevier.com/locate/mito Review Comprehensive review on lactate metabolism in human health☆,☆☆ M. Adeva-Andany a,⁎, M. López-Ojén b, R. Funcasta-Calderón a,1,E.Ameneiros-Rodrígueza,1, C. Donapetry-García a,1, M. Vila-Altesor a,1, J. Rodríguez-Seijas a,1 a Nephrology Division, Hospital General Juan Cardona, Ave. Pardo Bazán, s/n, 15406 Ferrol, La Coruña, Spain b Internal Medicine Division, Policlínica Assistens, c/Federico García, 4-planta baja, 15009 La Coruña, Spain article info abstract Article history: Metabolic pathways involved in lactate metabolism are important to understand the physiological response to Received 18 October 2013 exercise and the pathogenesis of prevalent diseases such as diabetes and cancer. Monocarboxylate transporters Received in revised form 19 March 2014 are being investigated as potential targets for diagnosis and therapy of these and other disorders. Glucose and al- Accepted 5 May 2014 anine produce pyruvate which is reduced to lactate by lactate dehydrogenase in the cytoplasm without oxygen Available online 12 June 2014 consumption. Lactate removal takes place via its oxidation to pyruvate by lactate dehydrogenase. Pyruvate may be either oxidized to carbon dioxide producing energy or transformed into glucose. Pyruvate oxidation requires Keywords: Glycolysis oxygen supply and the cooperation of pyruvate dehydrogenase, the tricarboxylic acid cycle, and the mitochondri- Tricarboxylic acid cycle al respiratory chain. Enzymes of the gluconeogenesis pathway sequentially convert pyruvate into glucose. Con- Respiratory chain genital or acquired deficiency on gluconeogenesis or pyruvate oxidation, including tissue hypoxia, may induce Gluconeogenesis lactate accumulation.
    [Show full text]
  • The Effects of Genetic Mutations and Drugs on the Activity of the Thiamine Transporter, SLC19A2
    UCSF UC San Francisco Previously Published Works Title The Effects of Genetic Mutations and Drugs on the Activity of the Thiamine Transporter, SLC19A2. Permalink https://escholarship.org/uc/item/0fb7q1fj Journal The AAPS journal, 23(2) ISSN 1550-7416 Authors Enogieru, Osatohanmwen J Koleske, Megan L Vora, Bianca et al. Publication Date 2021-03-01 DOI 10.1208/s12248-021-00562-4 Peer reviewed eScholarship.org Powered by the California Digital Library University of California The AAPS Journal (2021) 23:35 DOI: 10.1208/s12248-021-00562-4 Brief/Technical Note Theme: Celebrating Women in the Pharmaceutical Sciences Guest Editors: Diane Burgess, Marilyn Morris and Meena Subramanyam The Effects of Genetic Mutations and Drugs on the Activity of the Thiamine Transporter, SLC19A2 Osatohanmwen J. Enogieru,1 Megan L. Koleske,1 Bianca Vora,1 Huy Ngo,1 Sook Wah Yee,1 Derrick Chatad,2 Marina Sirota,3,4,5 and Kathleen M. Giacomini1,4 Received 11 November 2020; accepted 26 January 2021 Abstract. A rare cause of megaloblastic anemia (MA) is thiamine-responsive megalo- blastic anemia (TRMA), a genetic disorder caused by mutations in SLC19A2 (encoding THTR1), a thiamine transporter. The study objectives were to (1) functionally characterize selected TRMA-associated SLC19A2 variants and (2) determine whether current prescrip- tion drugs associated with drug-induced MA (DIMA) may act via inhibition of SLC19A2. Functional characterization of selected SLC19A2 variants was performed by confocal microscopy and isotopic uptake studies of [3H]-thiamine in HEK293 cells. Sixty-three drugs associated with DIMA were screened for SLC19A2 inhibition in isotopic uptake studies. Three previously uncharacterized SLC19A2 variants identified in TRMA patients exhibited disrupted localization to the plasma membrane along with near-complete loss-of-function.
    [Show full text]
  • Maternally Inherited Diabetes and Deafness (MIDD) Syndrome with M.3243A>G Mutation Associated with Renal Failure — a Case Report
    CASE REPORT ISSN 2450–7458 Grzegorz Kade1, Sebastian Krzysztof Spaleniak2, Bogdan Brodacki3, Agnieszka Pollak4, Dariusz Moczulski2, Monika Ołdak4, Marek Saracyn5 1Department of Internal Medicine, Nephrology and Dialysis, Military Institute of Medicine, Warsaw, Poland 2Department of Internal Medicine and Nephrodiabetology, Medical University of Lodz, Poland 3Neurological Clinic, Military Institute of Medicine, Warsaw, Poland 4Department of Genetics, Institute of Physiology and Pathology of Hearing, Warsaw, Poland 5Department of Endocrinology and Isotope Therapy, Military Institute of Medicine, Warsaw, Poland Maternally inherited diabetes and deafness (MIDD) syndrome with m.3243A>G mutation associated with renal failure — a case report ABSTRACT before as a cause of renal failure in MIDD patients. Maternally-inherited diabetes with deafness (MIDD) (Clin Diabetol 2020; 9; 6: 475–478) is a rare form of monogenic diabetes that results, in most cases, from an A-to-G transition at position 3243 Key words: mitochondrial diabetes, sensorineural of mitochondrial DNA (m.3243A>G). The clinical pres- deafness, m.3243A>G mutation, renal failure, entation of m.3243A>G mutation is variable, ranging incomplete distal renal tubular acidosis from mild to severe phenotypes. Diabetes is often accompanied by sensorineural deafness, cardiomyo- Introduction pathy, neuromuscular, psychiatric disorders, macular The relationship between the m.3243A>G muta- dystrophy and renal failure (kidney manifestations in tion and maternally inherited diabetes mellitus and adults presenting with this mutation remain poorly deafness syndrome (MIDD) was first described in 1992 defined). by Ballinger et al. [1] Another disease associated with The study presents a case of a 40-years-old woman this mitochondrial mutation is MELAS syndrome (mito- with a history of bilateral sensorineural deafness, chondrial encephalopathy, lactic acidosis, and stroke- renal failure and diabetes that was diagnosed due to like episodes) which has been described by Pavlakis et increasing muscle weakness during exercise.
    [Show full text]
  • Linking Vitamin B1 with Cancer Cell Metabolism Jason a Zastre*, Rebecca L Sweet, Bradley S Hanberry and Star Ye
    Zastre et al. Cancer & Metabolism 2013, 1:16 http://www.cancerandmetabolism.com/content/1/1/16 Cancer & Metabolism REVIEW Open Access Linking vitamin B1 with cancer cell metabolism Jason A Zastre*, Rebecca L Sweet, Bradley S Hanberry and Star Ye Abstract The resurgence of interest in cancer metabolism has linked alterations in the regulation and exploitation of metabolic pathways with an anabolic phenotype that increases biomass production for the replication of new daughter cells. To support the increase in the metabolic rate of cancer cells, a coordinated increase in the supply of nutrients, such as glucose and micronutrients functioning as enzyme cofactors is required. The majority of co- enzymes are water-soluble vitamins such as niacin, folic acid, pantothenic acid, pyridoxine, biotin, riboflavin and thiamine (Vitamin B1). Continuous dietary intake of these micronutrients is essential for maintaining normal health. How cancer cells adaptively regulate cellular homeostasis of cofactors and how they can regulate expression and function of metabolic enzymes in cancer is underappreciated. Exploitation of cofactor-dependent metabolic pathways with the advent of anti-folates highlights the potential vulnerabilities and importance of vitamins in cancer biology. Vitamin supplementation products are easily accessible and patients often perceive them as safe and beneficial without full knowledge of their effects. Thus, understanding the significance of enzyme cofactors in cancer cell metabolism will provide for important dietary strategies and new molecular targets to reduce disease progression. Recent studies have demonstrated the significance of thiamine-dependent enzymes in cancer cell metabolism. Therefore, this review discusses the current knowledge in the alterations in thiamine availability, homeostasis, and exploitation of thiamine-dependent pathways by cancer cells.
    [Show full text]
  • Disruption of Transport Activity in a D93H Mutant Thiamine Transporter 1, from a Rogers Syndrome Family
    Eur. J. Biochem. 270, 4469–4477 (2003) Ó FEBS2003 doi:10.1046/j.1432-1033.2003.03839.x Disruption of transport activity in a D93H mutant thiamine transporter 1, from a Rogers Syndrome family Dana Baron1, Yehuda G. Assaraf2, Stavit Drori2 and Ami Aronheim1 1Department of Molecular Genetics, The Rappaport Institute for Research in the Medical Sciences and the B. Rappaport Faculty of Medicine, and 2Department of Biology, The Technion-Israel Institute of Technology, Haifa, Israel Rogers syndrome is an autosomal recessive disorder result- transport null cells of a homologous D88H mutation in ing in megaloblastic anemia, diabetes mellitus, and sensori- the hRFC did not result in restoration of MTX trans- neural deafness. The gene associated with this disease port activity, thereby suggesting that D88 is an essential encodes for thiamine transporter 1 (THTR1), a member of residue for MTX transport activity. These results suggest the SLC19 solute carrier family including THTR2 and the that the D93H mutation does not interfere with trans- reduced folate carrier (RFC). Using transient transfections porter expression, glycosylation and plasma membrane into NIH3T3 cells of a D93H mutant THTR1 derived targeting. However, the substitution of this negatively from a Rogers syndrome family, we determined the charged amino acid (Asp93) by a positively charged expression, post-translational modification, plasma mem- residue (His) in an extremely conserved region (the bor- brane targeting and thiamine transport activity. We also der of transmembrane domain 2/intracellular loop 2) in explored the impact on methotrexate (MTX) transport the SLC19 family, presumably inflicts deleterious struc- activity of a homologous missense D88H mutation in the tural alterations that abolish thiamine binding and/or human RFC, a close homologue of THTR1.
    [Show full text]
  • The Concise Guide to PHARMACOLOGY 2015/16: Transporters
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: Transporters. British Journal of Pharmacology (2015) 172, 6110–6202 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: Transporters Stephen PH Alexander1, Eamonn Kelly2, Neil Marrion2, John A Peters3, Helen E Benson4, Elena Faccenda4, Adam J Pawson4, Joanna L Sharman4, Christopher Southan4, Jamie A Davies4 and CGTP Collaborators L 1 School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2 School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK 3 Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK N 4 Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13355/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The Concise Guide is published in landscape format in order to facilitate comparison of related targets.
    [Show full text]
  • The Role of Mitochondrial Mutations and Chronic Inflammation in Diabetes
    International Journal of Molecular Sciences Review The Role of Mitochondrial Mutations and Chronic Inflammation in Diabetes Siarhei A. Dabravolski 1, Varvara A. Orekhova 2,*, Mirza S. Baig 3, Evgeny E. Bezsonov 2,4 , Antonina V. Starodubova 5,6 , Tatyana V. Popkova 7 and Alexander N. Orekhov 2,4 1 Department of Clinical Diagnostics, Vitebsk State Academy of Veterinary Medicine, 210026 Vitebsk, Belarus; [email protected] 2 Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia; [email protected] (E.E.B.); [email protected] (A.N.O.) 3 Department of Biosciences and Biomedical Engineering (BSBE), Indian Institute of Technology Indore (IITI), Simrol 456552, India; [email protected] 4 Institute of Human Morphology, 117418 Moscow, Russia 5 Federal Research Centre for Nutrition, Biotechnology and Food Safety, 109240 Moscow, Russia; [email protected] 6 Therapy Faculty, Pirogov Russian National Research Medical University, 117997 Moscow, Russia 7 V.A. Nasonova Institute of Rheumatology, 115522 Moscow, Russia; [email protected] * Correspondence: [email protected]; Tel.: +7-(495)-415-95-94; Fax: +7-(495)-415-95-94 Abstract: Diabetes mellitus and related disorders significantly contribute to morbidity and mortality worldwide. Despite the advances in the current therapeutic methods, further development of anti- diabetic therapies is necessary. Mitochondrial dysfunction is known to be implicated in diabetes development. Moreover, specific types of mitochondrial diabetes have been discovered, such as MIDD (maternally inherited diabetes and deafness) and DAD (diabetes and Deafness). Hereditary Citation: Dabravolski, S.A.; mitochondrial disorders are caused by certain mutations in the mitochondrial DNA (mtDNA), which Orekhova, V.A.; Baig, M.S.; Bezsonov, encodes for a substantial part of mitochondrial proteins and mitochondrial tRNA necessary for E.E.; Starodubova, A.V.; Popkova, T.V.; Orekhov, A.N.
    [Show full text]
  • Mitochondrial Diseases in North America an Analysis of the NAMDC Registry
    ARTICLE OPEN ACCESS Mitochondrial diseases in North America An analysis of the NAMDC Registry Emanuele Barca, MD, PhD, Yuelin Long, MS, Victoria Cooley, MS, Robert Schoenaker, MD, BS, Correspondence Valentina Emmanuele, MD, PhD, Salvatore DiMauro, MD, Bruce H. Cohen, MD, Amel Karaa, MD, Dr. Hirano [email protected] Georgirene D. Vladutiu, PhD, Richard Haas, MBBChir, Johan L.K. Van Hove, MD, PhD, Fernando Scaglia, MD, Sumit Parikh, MD, Jirair K. Bedoyan, MD, PhD, Susanne D. DeBrosse, MD, Ralitza H. Gavrilova, MD, Russell P. Saneto, DO, PhD, Gregory M. Enns, MBChB, Peter W. Stacpoole, MD, PhD, Jaya Ganesh, MD, Austin Larson, MD, Zarazuela Zolkipli-Cunningham, MD, Marni J. Falk, MD, Amy C. Goldstein, MD, Mark Tarnopolsky, MD, PhD, Andrea Gropman, MD, Kathryn Camp, MS, RD, Danuta Krotoski, PhD, Kristin Engelstad, MS, Xiomara Q. Rosales, MD, Joshua Kriger, MS, Johnston Grier, MS, Richard Buchsbaum, John L.P. Thompson, PhD, and Michio Hirano, MD Neurol Genet 2020;6:e402. doi:10.1212/NXG.0000000000000402 Abstract Objective To describe clinical, biochemical, and genetic features of participants with mitochondrial diseases (MtDs) enrolled in the North American Mitochondrial Disease Consortium (NAMDC) Registry. Methods This cross-sectional, multicenter, retrospective database analysis evaluates the phenotypic and molecular characteristics of participants enrolled in the NAMDC Registry from September 2011 to December 2018. The NAMDC is a network of 17 centers with expertise in MtDs and includes both adult and pediatric specialists. Results One thousand four hundred ten of 1,553 participants had sufficient clinical data for analysis. For this study, we included only participants with molecular genetic diagnoses (n = 666).
    [Show full text]